Savant Capital LLC Purchases 350 Shares of Boston Scientific Co. (NYSE:BSX)

Savant Capital LLC boosted its position in Boston Scientific Co. (NYSE:BSX) by 2.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 12,955 shares of the medical equipment provider’s stock after acquiring an additional 350 shares during the quarter. Savant Capital LLC’s holdings in Boston Scientific were worth $749,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in BSX. BSW Wealth Partners lifted its holdings in shares of Boston Scientific by 2.3% in the fourth quarter. BSW Wealth Partners now owns 7,398 shares of the medical equipment provider’s stock worth $428,000 after acquiring an additional 165 shares during the last quarter. Valley National Advisers Inc. grew its stake in shares of Boston Scientific by 2.3% during the fourth quarter. Valley National Advisers Inc. now owns 7,526 shares of the medical equipment provider’s stock worth $435,000 after buying an additional 170 shares during the last quarter. Whitaker Myers Wealth Managers LTD. increased its holdings in shares of Boston Scientific by 4.6% during the fourth quarter. Whitaker Myers Wealth Managers LTD. now owns 4,093 shares of the medical equipment provider’s stock worth $237,000 after buying an additional 179 shares in the last quarter. Brighton Jones LLC lifted its stake in shares of Boston Scientific by 5.4% in the 3rd quarter. Brighton Jones LLC now owns 3,999 shares of the medical equipment provider’s stock valued at $211,000 after acquiring an additional 205 shares during the last quarter. Finally, Altfest L J & Co. Inc. boosted its holdings in shares of Boston Scientific by 1.6% during the 3rd quarter. Altfest L J & Co. Inc. now owns 13,298 shares of the medical equipment provider’s stock valued at $702,000 after acquiring an additional 208 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

BSX has been the subject of a number of recent research reports. JPMorgan Chase & Co. upped their target price on Boston Scientific from $72.00 to $82.00 and gave the stock an “overweight” rating in a report on Thursday, April 25th. Needham & Company LLC raised their price objective on shares of Boston Scientific from $71.00 to $82.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Royal Bank of Canada boosted their target price on shares of Boston Scientific from $78.00 to $82.00 and gave the stock an “outperform” rating in a report on Thursday, April 25th. Robert W. Baird raised their price target on shares of Boston Scientific from $79.00 to $84.00 and gave the company an “outperform” rating in a research note on Thursday, April 25th. Finally, Evercore ISI boosted their price objective on shares of Boston Scientific from $72.00 to $78.00 and gave the stock an “outperform” rating in a research note on Thursday, April 25th. Three equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and an average target price of $75.09.

Boston Scientific Stock Performance

NYSE:BSX opened at $72.85 on Friday. The company has a quick ratio of 0.82, a current ratio of 1.66 and a debt-to-equity ratio of 0.47. Boston Scientific Co. has a twelve month low of $48.35 and a twelve month high of $74.39. The company has a fifty day moving average of $68.42 and a 200-day moving average of $61.27. The firm has a market capitalization of $106.88 billion, a P/E ratio of 61.22, a P/E/G ratio of 2.48 and a beta of 0.77.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.51 by $0.04. The firm had revenue of $3.73 billion during the quarter, compared to the consensus estimate of $3.59 billion. Boston Scientific had a net margin of 12.06% and a return on equity of 16.39%. During the same period in the previous year, the firm posted $0.45 earnings per share. As a group, sell-side analysts anticipate that Boston Scientific Co. will post 2.32 EPS for the current year.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig sold 7,000 shares of the stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $65.03, for a total value of $455,210.00. Following the transaction, the director now owns 41,374 shares in the company, valued at $2,690,551.22. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, Director Edward J. Ludwig sold 7,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $65.03, for a total transaction of $455,210.00. Following the transaction, the director now directly owns 41,374 shares of the company’s stock, valued at $2,690,551.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Edward J. Ludwig sold 9,818 shares of Boston Scientific stock in a transaction on Friday, April 26th. The shares were sold at an average price of $73.29, for a total transaction of $719,561.22. Following the completion of the sale, the director now directly owns 41,374 shares of the company’s stock, valued at approximately $3,032,300.46. The disclosure for this sale can be found here. Insiders sold 78,384 shares of company stock valued at $5,395,560 in the last three months. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.